In patients with NAFLD, 12 weeks of the 16:8 TRF did not lead to differences in fasting glucose and insulin levels compared to the control group, regardless of the reduction in body weight reported, in the study by Cai et al. [39]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.